NOTABLE LABS, LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.975 USD | +0.52% |
|
-15.95% | -48.41% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 8.79M |
|---|---|---|---|---|---|
| Net income 2024 * | -14M | Net income 2025 * | -19M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.65
x | P/E ratio 2025 * |
-0.36
x | Employees | 16 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Notable Labs, Ltd.
More recommendations
More press releases
| 1 day | +0.52% | ||
| 1 week | -15.95% | ||
| Current month | -44.92% | ||
| 1 month | -40.91% | ||
| 3 months | -15.95% | ||
| 6 months | -69.15% | ||
| Current year | -48.41% |
1 week
0.83
1.32
1 month
0.831.94
Current year
0.832.02
1 year
0.835.27
3 years
0.835.27
5 years
0.835.27
10 years
0.835.27
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.975 | +0.52% | 39,533 |
| 24-04-18 | 0.97 | +1.04% | 82,691 |
| 24-04-17 | 0.96 | -2.55% | 58,934 |
| 24-04-16 | 0.9851 | -16.50% | 214,543 |
| 24-04-15 | 1.18 | +1.71% | 94,267 |
End-of-day quote Nasdaq, April 18, 2024
More quotes
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.975
USD
Average target price
8
USD
Spread / Average Target
+720.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.41% | 8.75M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- NTBL Stock
